ORBIMED ADVISORS LLC 13D and 13G filings for Fusion Pharmaceuticals Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-05-16 4:28 pm Unchanged | 2023-05-11 | 13D | Fusion Pharmaceuticals Inc. FUSN | ORBIMED ADVISORS LLC | 2,930,670 4.600% | 0 (Unchanged) | Filing |
| 2023-02-28 5:09 pm Sale | 2023-02-16 | 13D | Fusion Pharmaceuticals Inc. FUSN | ORBIMED ADVISORS LLC | 2,930,670 4.700% | -67,311 (-2.25%) | Filing |
| 2020-07-06 5:57 pm Purchase | 2020-06-30 | 13D | Fusion Pharmaceuticals Inc. FUSN | ORBIMED ADVISORS LLC | 2,997,981 7.200% | 2,997,981 (New Position) | Filing |